New triple therapy targets hard-to-treat breast cancers

NCT ID NCT02393794

Ongoing Disease control Sponsor: Priyanka Sharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs—cisplatin, romidepsin, and nivolumab—in people with advanced triple-negative breast cancer or BRCA-related breast cancer that has spread. The goal is to see if the combination can shrink tumors and control the disease. About 51 participants will receive the treatment, and researchers will monitor response and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA MUTATION-ASSOCIATED LOCALLY RECURRENT OR METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hereditary breast ovarian cancer syndrome triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

University of Kansas Cancer Center - Clinical Research Center

Fairway, Kansas, 66205, United States
University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064, United States
University of Kansas Cancer Center - North

Kansas City, Missouri, 64154, United States
University of Kansas Cancer Center - Overland Park

Overland Park, Kansas, 66210, United States
University of Kansas Cancer Center - South

Kansas City, Missouri, 64131, United States
University of Kansas Cancer Center - West

Kansas City, Kansas, 66112, United States
University of Kansas Cancer Center - Westwood

Westwood, Kansas, 66205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.